Sold as Navelbine. Every FDA application for this active ingredient: 1 branded and 11 generic. Boxed warning
As of Nov 22, 2026, FDA lists 12 applications for Vinorelbine tartrate (sold as Navelbine), first approved Dec 23, 1994, with 2 new uses approved and 0 published complete response letters.
| Dec 23, 1994 | NavelbineNDA 20388 · New molecular entity | Pierre Fabre | 22 | Discontinued |
| Feb 3, 2003 | Vinorelbine TartrateANDA 76028 | Teva Pharmaceuticals USA | 1 | Discontinued |
| Jun 10, 2003 | Vinorelbine TartrateANDA 75992 | Hikma Pharmaceuticals | 0 | Marketed |
| Dec 11, 2003 | Vinorelbine TartrateANDA 76461 | Hikma Pharmaceuticals | 0 | Marketed |
| Apr 18, 2005 | Vinorelbine TartrateANDA 76849 | Fresenius Kabi USA | 0 | Discontinued |
| Jun 2, 2005 | Vinorelbine TartrateANDA 76827 | Hospira | 2 | Discontinued |
| Feb 13, 2008 | Vinorelbine TartrateANDA 78408 | Ebewe Pharma | 0 | Discontinued |
| Jul 22, 2009 | Vinorelbine TartrateANDA 78011 | Actavis Totowa | 4 | Marketed |
| Aug 31, 2012 | Vinorelbine TartrateANDA 200148 | Rising Pharmaceuticals | 2 | Discontinued |
| Sep 26, 2012 | Vinorelbine TartrateANDA 91106 | Jiangsu Hansoh Pharmaceutical | 4 | Marketed |
| Sep 12, 2013 | Vinorelbine TartrateANDA 202017 | Dr. Reddy's Laboratories | 1 | Marketed |
| Aug 5, 2019 | Vinorelbine TartrateANDA 208997 | Ingenus Pharmaceuticals | 1 | Discontinued |
| Navelbine | Part B | $56K | −41% | 311 |
| Vinorelbine Tartrate | Part D | $18K | +4% | 33 |
Of the 69 whose ending is known, 29% met their primary endpoint, 17% missed it and 54% stopped early.
| Low-Dose Apatinib Plus Chemotherapy in ADC-Pretreated HER2-Positive and HER2-Low Advanced Breast CancerBreast Neoplasms, Advanced Breast Cancer · Yunnan Cancer Hospital | Phase 2 | Not yet recruiting | Oct 30, 2026 |
| Implantable Microdevices for in Situ Evaluation of Drug Responses in Lung CancerLung Cancer, Mesothelioma · Oliver Jonas | Early phase 1 | Recruiting | Oct 23, 2026 |
| A Phase II Study of HLX22 in Combination With Trastuzumab and Chemotherapy in HER2-Positive Locally Advanced or Metastatic Breast Cancer PatientsHER2 + Breast Cancer · Shanghai Henlius Biotech | Phase 2 | Not yet recruiting | Sep 17, 2026 |
| A Phase 3 Trial in Advanced Epithelioid MesotheliomaPleural Mesothelioma, Mesothelioma · Vivace Therapeutics, Inc | Phase 3 | Not yet recruiting | Sep 17, 2026 |
| Optimal Application Timing of ADC Drugs for Advanced Breast CancerBreast Cancer Females · Liaoning Cancer Hospital & Institute | Phase 2 | Recruiting | Jun 18, 2026 |
| Neoadjuvant Trastuzumab, Pertuzumab Plus Metronomic Vinorelbine for Elderly HER2-Positive Breast CancerNeoadjuvant Therapy in Elderly HER2-Positive Breast Cancer · Tianjin Medical University Cancer Institute and Hospital | Not applicable | Not yet recruiting | May 15, 2026 |
| A Study of 9MW2821 Versus Chemotherapy in Participants With Previously Treated Locally Advanced or Metastatic Triple-Negative Breast CancerLocally Advanced or Metastatic Triple-negative Breast Cancer · Mabwell (Shanghai) Bioscience Co., Ltd. | Phase 3 | Not yet recruiting | Apr 29, 2026 |
| Real-world Patient-reported Outcome of Sacituzumab Govitecan in Chinese Metastatic Breast CancerTNBC - Triple-Negative Breast Cancer · Fudan University | — | Recruiting | Apr 24, 2026 |
Applications, approvals and products come from FDA's Drugs@FDA data files, refreshed weekly, grouped by active ingredient as FDA spells it. Complete response letters are FDA's published letters. Medicare spending is CMS's Part D and Part B dashboard, matched to this ingredient by generic name; shortages are FDA's shortage list, matched by application number; clinical trials are ClinicalTrials.gov studies naming the ingredient as an intervention, refreshed daily; safety programs are FDA's REMS list, matched by application number or, for shared programs, by ingredient. Mechanisms, targets, withdrawals and boxed warnings are from ChEMBL (EMBL-EBI, CC BY-SA 3.0), matched by ingredient name. How trials ended is TrialPanorama's classification of ClinicalTrials.gov records (Wang et al. 2025, Apache-2.0), matched by the intervention name each trial registered. Drugs@FDA